GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » Retained Earnings

Artelo Biosciences (Artelo Biosciences) Retained Earnings : $-42.79 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Artelo Biosciences's retained earnings for the quarter that ended in Mar. 2024 was $-42.79 Mil.

Artelo Biosciences's quarterly retained earnings declined from Sep. 2023 ($-37.24 Mil) to Dec. 2023 ($-40.31 Mil) and declined from Dec. 2023 ($-40.31 Mil) to Mar. 2024 ($-42.79 Mil).

Artelo Biosciences's annual retained earnings declined from Aug. 2021 ($-16.90 Mil) to Dec. 2022 ($-31.02 Mil) and declined from Dec. 2022 ($-31.02 Mil) to Dec. 2023 ($-40.31 Mil).


Artelo Biosciences Retained Earnings Historical Data

The historical data trend for Artelo Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Retained Earnings Chart

Artelo Biosciences Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.81 -9.47 -16.90 -31.02 -40.31

Artelo Biosciences Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.19 -34.79 -37.24 -40.31 -42.79

Artelo Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Artelo Biosciences  (NAS:ARTLW) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Artelo Biosciences (Artelo Biosciences) Business Description

Traded in Other Exchanges
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Artelo Biosciences (Artelo Biosciences) Headlines